Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.42 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574523 | 0.79 | RAB9A (0.42) | NPC1RAB9ASMN1; SMN2KDM4EGPR3 | |
| SCHEMBL17048132 | 0.76 | METAP2 (0.41) | RAB9ASMN1; SMN2KDM4EGPR3ALDH1A1 | |
| SCHEMBL2459241 | 0.75 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2BCHEKDM4E | |
| SCHEMBL317014 | 0.74 | GPR3 (0.41) | NPC1RAB9AKDM4EGPR3ALDH1A1 | |
| SCHEMBL2065802 | 0.73 | CYP1A2 (0.49) | NPC1RAB9ASMN1; SMN2KDM4EGPR3 | |
| SCHEMBL1725498 | 0.72 | DHODH (0.40) | GPR3 | |
| SCHEMBL29942654 | 0.72 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2BCHEKDM4E | |
| SCHEMBL29614829 | 0.72 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2BCHEKDM4E | |
| SCHEMBL29966674 | 0.72 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2BCHEKDM4E | |
| SCHEMBL3076524 | 0.72 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2BCHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0382628-B1 | Aminoalkoxylphenyl derivatives, process for their preparation and compositions containing them | SANOFI ELF (FR) | 1994-05-04 | — | — | EP | claimed |
| EP-0382628-A1 | Aminoalkoxylphenyl derivatives, process for their preparation and compositions containing them | ELF SANOFI (FR) | 1990-08-16 | — | — | EP | claimed |
| EP-2106401-B1 | DERIVATIVES OF PYRROLOPYRIDINE-2-CARBOXAMIDS, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-03-14 | — | — | EP | disclosed |
| US-8044066-B2 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20090298865-A1 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| EP-2106401-A2 | DERIVATIVES OF PYRROLOPYRIDINE-2-CARBOXAMIDS, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2009-10-07 | — | — | EP | disclosed |
| WO-2008107543-A2 | DERIVATIVES OF PYRROLOPYRIDINE-2-CARBOXAMIDS, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-09-12 | — | — | WO | disclosed |
| EP-1725526-A2 | METHOD FOR PREPARING PYRROLIDINE OXIMES | Applied Research Systems ARS Holding N.V. (AN) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005082848-A2 | METHOD FOR PREPARING PYRROLIDINE OXIMES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298865-A1 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | PYCR1, ATP5PD, NQO2 | NPC1 2399/4885RAB9A 2865/4885SMN1; SMN2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.